Cytomegalovirus infection in patients with HIV infection

Mount Sinai Journal of Medicine

Volumn 66, Issue 2, 1999, Pages 113-124

  Cheung, Tony W ^a   Teich, Steven A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; CMV colitis; Cytomegalovirus infection; Human immunodeficiency virus

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COLITIS; CYTOMEGALOVIRUS INFECTION; ESOPHAGITIS; GASTROINTESTINAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; RETINITIS; REVIEW; VIRUS PNEUMONIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; FOSCARNET; GANCICLOVIR; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 0033018329     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988, 108:585-594.
2. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med 1988; 109:963-969.
3. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14:608-615.
4. Schooley RT. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis 1990; 12 Suppl 7:S811-S819.
5. Drew WL, Mintz L, Miner RC, Ketterer B. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981; 143:188-192.
6. Palestine AG, Polis MA, De Smet MD, et al A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-673.
7. Crowe SM, Carlin JB, Stewart KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected person. J Acquir Immune Defic Syndr 1991; 4:770-776.
8. Gallant JE, Moore RD, Richman DD, et al. Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus treated with zidovudine. J Infect Dis 1992; 166:1223-1227.
9. Hoover, DR, Saah AJ, Bacellar H, et al. Clinical manifestation of AIDS in the era of Pneumocystis prophylaxis: Multicenter AIDS cohort study. N Engl J Med 1993; 329:1922-1926.
10. Kupperman BD, Petty JG, Richman DD, et al. Correlation between CD4 counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993; 115:575-582.
11. Hartstein ME, Chin PK, Ku CW, Pak S. CMV retinitis screening in an urban population. In: Association for Research in Vision and Ophthalmology (ARVO). Proceedings of the Invest Ophthalmol Vis Sci Annual Meeting; 1994 May 1-4; Sarasota, FL. Bethesda, MD: ARVO; 1994, 35(S); [Abstract 2961].
12. Morlet N, Young S, Corneo MT. Risk factors for the development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1994; 118:684-685.
13. Bachman DM, Bruni LM, DiGioia RA, et al. Visual field testing in the management of cytomegalovirus retinitis. Ophthalmology 1992; 99:1393-1399.
14. Teich SA, Saltzman BR. Evaluation of a new self-screening chart for cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:336-342.
15. Orellana J, Lieberman RM, Teich SA. Color atlas of ocular manifestations of AIDS. Igaku and New York: Shoin Medical Publishers, Inc.; 1995. pp. 46-49.
16. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitreitis associated with inactive cytomegalovirus retinitis: A new syndrome. Arch Ophthalmol 1998; 116:169-175.
17. Jabs DA. Treatment of cytomegalovirus retinitis - 1992. Arch Ophthalmol 1992; 110:185-187.
18. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107:75-80.
19. O'Donnell JJ, Jacobson MA. Cotton-wool spots and cytomegalovirus in AIDS. Int Ophthalmol Clin 1987; 29:105-107.
20. Margolis TP, Lowder CY, Holland GN, et al. Varicella-zoster virus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1991; 112:119-131.
21. Holland GN, Engstrom RE, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988; 106:653-657.
22. Dugel PU, Rao NA, Forster DJ, et al. Pneumocystis carinii choroiditis after long-term aerosolized pentamidine therapy. Am J Ophthalmol 1990, 110:113-117.
23. Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991; 109:794-799.
24. The Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 1997, 124:61-70.
25. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for the development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993; 116:713-720.
26. Lim JI, Enger C, Haller JA, et al. Improved visual results after surgical repair of cytomegalovirus-related retinal detachments. Ophthalmology 1994; 101:264-269.
27. Kupperman BD, Flores-Aguilar M, Quiceno JI, et al. A masked prospective evaluation of outcome parameters for cytomegalovirus related retinal detachment surgery in patients with acquired immune deficiency syndrome. Ophthalmology 1994; 101:46-55.
28. Davis JL, Serfaas MS, Mei Ying L, et al. Silicone oil in repair of retinal detachment caused by necrotizing retinitis in HIV infection. Arch Ophthalmol 1995; 113:1401-1409.
29. Wilcox CM. Esophageal disease in the acquired immunodeficiency syndrome: Etiology, diagnosis and management Am J Med 1992; 92:412-421.
30. Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection. Causes, response to therapy, and long-term outcome. Ann Intern Med 1995; 123:143-149.
31. Frager DH, Frager JD, Wolf EL, et al. Cytomegalovirus colitis in acquired immune deficiency syndrome: Radiologic spectrum. Gastrointest Radiol 1986; 11:241-246.
32. Wilcox CM, Forsmark CE, Grendell JH, et al. Cytomegalovirus-associated acute pancreatic disease in patients with acquired immunodeficiency syndrome. Report of two patients. Gastroenterology 1990; 99:263-267.
33. Bonacini M. Pancreatic involvement in human immunodeficiency virus infection. J Clin Gastrointestinal 1991; 13:58-64.
34. Brivet FG, Naveau SH, Legmaigne GF, Dormont J. Pancreatic lesions in HIV-infected patients. Baillieres Clin Endocrinol Metab 1994; 8:859-877.
35. Murray JF, Felton CP, Garay SM, et al. Pulmonary complications of the acquired immunodeficiency syndrome: Report of a National Heart, Lung and Blood Institute Workshop. N Engl J Med 1984; 310:1682-1688.
36. Wallace JM, Hannah J. Cytomegalovirus pneumonitis in patients with AIDS. Findings in an autopsy series. Chest 1987; 82:198-203.
37. Jacobson MA, Mills J, Rush J, et al. Morbidity and mortality of patients with AIDS and first episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis 1991; 144 6-9.
38. McKenzie R, Travis WD, Dolan SA, et al The causes of death in patients with human immunodeficiency virus infection: A clinical and pathologic study with emphasis on the role of pulmonary disease. Medicine (Baltimore) 1991; 70 326-343.
39. Petito CK, Cho ES, Lemann W, et al Neuropathology of acquired immunodeficiency syndrome (AIDS): An autopsy review. J Neuropathol Exp Neurol 1986; 45:635-646.
40. Morgello S, Cho ES, Nielson S, et al. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: An autopsy study of 30 cases and a review of the literature. Hum Pathol 1987; 18:289-297.
41. Simpson DM, Taglieti M. Neurologic manifestations of HIV infection. Ann Intern Med 1994; 121:769-785
42. Behar R, Wiley C, McCutchan JA. Cytomegalovirus polyradiculopathy in acquired immune deficiency syndrome. Neurology 1987; 37:557-561.
43. Said G, La Croix C, Chemouilli P, et al. Cytomegalovirus, neuropathy in acquired immunodeficiency syndrome. A clinical and pathologic study. Ann Neurol 1991; 29:139-146.
44. Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990; 40:569-574.
45. Bylsma SS, Achim CL, Wiley CA, et al. The predictive value of cytomegalovirus retinitis for cytomegalovirus encephalitis in acquired immunodeficiency syndrome. Arch Ophthalmol 1995; 113:89-95.
46. Weber B, Hamann A, Ritt B, et al. Comparison of shell vial culture and serology for the diagnosis of human cytomegalovirus infection in neonates and immunocompromised subjects. Clin Invest Med 1992; 70:503-507.
47. Rasmussen L, Morris S, Zoipeto D, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinins. J Infect Dis 1995; 171:177-182.
48. Grefte JM, van der Gun BT, Schmolke S, et al. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 1992; 73:2923-2932.
49. Dodt KK, Jacobsen PH, Hofmann B, et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997; 11:F21-F28.
50. Shinkai M, Bozette SA, Powderly W, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997; 175:302-308.
51. Chernoff DN, Miner RC, Hoo BS, et al. Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay. J Clin Microbiol 1997; 35:2740-2744.
52. Buhles WC, Mastre BJ, Tinker AJ, et al. Syntex Collaborative Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection experience in 314 immunocompromised patients Rev Infect Dis 1998; 10 Suppl 3:S495-S504.
53. Spector SA, Barker C, Buhles WC, et al. A randomized, controlled study of immediate vs deferred ganciclovir therapy in AIDS patients with cytomegalovirus peripheral retinitis. In: International AIDS Society. Proceedings of the 7th International Conference on AIDS; 1991 Jun 16-21; Florence, Italy. Rome, Italy: Institute Superiore di Sanita; 1991. [Abstract MB-86].
54. Study of the Ocular Complications of AIDS Research Group and AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213-220.
55. Erice A, Chou S, Biron KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320:289-293.
56. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163:716-719.
57. Jacobson MA, O'Donnell JJ, Rousell R, et al. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: A phase I study. Antimicrob Agents Chemother 1990; 34:176-178.
58. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology 1989; 96:367-374.
59. Schulman J, Peyman GA, Horton MR, et al. Intraocular 9-([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration. Ophthalmic Surg 1986; 17:429-432.
60. Young SH, Morlet N, Heery S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992; 157:370-373.
61. Saran BR, Maguire AM. Retinal toxicity of high dose intravitreal ganciclovir. Retina 1994; 14:248-252.
62. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized, controlled clinical trial. Arch Ophthalmol 1994; 112:1531-1539.
63. Musch DC, Martin DF, Gordon JF, et al., and the Ganciclovir Implant Study Group. Treatment of cytomegalovirus retinitis with a sustazned-release ganciclovir implant. N Engl J Med 1997; 337:83-90.
64. Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 155:65-74.
65. Martin DR, Kupperman BD, Wolitz R, et al., and Roche Ganciclovir Study Group. Combined oral ganciclovir (GCV) and intravitreal GCV implant for treatment of patients with cytomegalovirus (CMV) retinitis: A randomized controlled trial. In: American Society Microbiology. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 18 - Oct 1; Toronto, Canada. Washington, DC: American Society Microbiology; 1997. [Abstract LB-9].
66. Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17:425-432.
67. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetics, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A phase I/II study. J Infect Dis 1995; 171:1431-1437.
68. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J Infect Dis 1985; 152:833-834.
69. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333:615-620.
70. Holland GN, Tufail A. New therapies for cytomegalovirus retinitis. N Engl J Med 1995; 333:658-659.
71. Lalezari JP, Fridberg D, Bisset J, et al. A comparison of the safety and efficacy of 3g, 4.5g, and 6g doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis. In: XI International Conference on AIDS Society. Proceedings of the 11th International AIDS Conference. 1996; Vancouver, Canada. Vancouver, Canada; XI International Conference on AIDS Society; 1996. [Abstract Th. B-305].
72. Erikson B, Öberg B, Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982; 696:115-123.
73. Sandstrom EG, Byington RE, Kaplan JC, Hirsch MS. Inhibition of human T-cell lymphotrophic virus type III in vitro by phosphonoformate. Lancet 1985; i:1480-1482.
74. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Antimcrob Agents Chemother 1989; 33:736-741.
75. Walmsley SL, Chew E, Read SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 1988; 157:569-572.
76. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr 1990; 3:472-479.
77. Studies of the Ocular Complication of AIDS (SOCA) and the AIDS Clinical Trials Group (ACTG). Antiretroviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172:613-621.
78. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991; 163:1348-1351.
79. Dunn JP, MacCumber MW, Forman MS, et al. Viral sensitivity testing in patient with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995; 119:587-596.
80. Diaz-Eliopis M, Chippoint E, Sachez S, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1992; 114:742-747.
81. Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreal foscarnet in a patient with AIDS. N Engl J Med 1994; 330:868-869.
82. Dieterich D, Dicker M, Tepper R. Foscarnet treatment of cytomegalovirus gastrointestinal infections in AIDS patients who failed ganciclovir. In: International AIDS Society. Proceedings of the 7th International Conference on AIDS; 1991 Jun 16-21, Florence, Italy. Rome, Italy: Institute Superiori di Sanita; 1991. [Abstract WB-2293].
83. Weinberg DV, Murphy R, Naughton K. Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. Am J Ophthalmol 1994; 117:776-782.
84. Flores-Aguilar M, Kupperman BD, Quiceno JI, et al. Pathophysiology and treatment of clinically-resistant cytomegalovirus retinitis. Ophthalmology 1993; 100:1022-1031.
85. Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infections in AIDS patients. J Infect Dis 1993; 167:1184-1188.
86. Kupperman BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1993; 11:1359-1366.
87. Studies of the Ocular Complication of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis patients with AIDS. Arch Ophthalmol 1996; 114:23-33.
88. Holland GN, Levinson, RD, Jacobson MA, and the AIDS Clinical Trials Group Protocol 915 Team. Dose-related difference in progression rates of cytomegalovirus retinopathy during the foscarnet maintenance therapy. Am J Ophthalmol 1995; 119:576-586.
89. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993; 168:444-448.
90. Yang H, Datema R. Prolonged and potent therapeutic and prophylactic effects of (s)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl] cytosine against herpes simplex type 2 infections in mice. Antimicrob Agents Chemother 1991; 35:1596-1600.
91. Lalezari JP, Holland GN, Stagg R, et al. A randomized, controlled study of cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS. In: American Society Microbiology. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20: San Francisco, CA. Washington, DC: American Society Microbiology; 1997. [Abstract LB-9].
92. Studies of Ocular Complication of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group: Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med 1997; 126:264-274.
93. Lalezari JP, Stagg RJ, Kupperman BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126:257-263.
94. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733-737.
95. Friedberg DN. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:801-802.
96. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491-1497.
97. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12:269-277.
98. Feinberg J, Cooper D, Hurwitz S. Phase III study of valaciclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease. In: American Society Microbiology. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco, CA. Washington, DC: American Society Microbiology; 1995. [Abstract 1-214].
99. Kirsch LS, Arevalo JF, DeClercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995; 119:466-476.
100. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMC) treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Ophthalmology 1995; 102:533-542. (Published erratum appears in Ophthalmology 1995; 102:702.)
101. Hutcherson SL, Palestine AG, Cantrill HL, et al. Anti-sense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients. In: American Society Microbiology. Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20: San Francisco, CA. Washington, DC: American Society Microbiology; 1995 [Abstract H-136].
102. Lalezari JP, Drew WL, Jordan C, et al. In vivo anti-CMV activity and safety of oral lobucavir in HIV-infected patients. In: Infectious Diseases Society of America (IDSA). Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC. Alexandria, VA: IDSA; 1997. [Abstract 301].
103. Zacny VL, Chamberlain SD, Townsend LB, et al. Activity against Epstein-Barr virus of benzimidazole riboside 126 W 94 (5,6 dichloro-2 (isoproylamino) -1-beta-L-ribofuranosyl-1H-benzimidazoles). In: American Society Microbiology. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28 - Oct 1; Toronto, Canada. Washington, DC: American Society Microbiology; 1997. [Abstract H-69].
104. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997; 277:1519-1520
105. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997; 124:199-205.
106. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-1445.